Sant Joan

Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting

Retrieved on: 
星期六, 六月 1, 2024
Aes, Bronchospasm, Comment, Patient, Annual general meeting, McCormick Place, Sant Joan, DCH, Cancer, Abdominal pain, Society, Therapy, Radioimmunotherapy, Bone marrow, Disease, Granulocyte-macrophage colony-stimulating factor, Pain, Hypotension, MBBS, Poster, MSK, MRCP, Pharmaceutical industry

The results are summarized in poster presentations scheduled to be presented today, June 1, 2024, at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, IL.

Key Points: 
  • The results are summarized in poster presentations scheduled to be presented today, June 1, 2024, at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, IL.
  • The Trial 201 prespecified interim analysis achieved a 50% overall response rate (“ORR”) in 26 out of 52 patients.
  • Nearly a quarter of patients achieved their first complete response (“CR”) or partial response (“PR”) after three or more cycles of naxitamab therapy.
  • These results support the rationale for extended naxitamab therapy in patients who do not achieve a CR or PR at first assessment.

Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma

Retrieved on: 
星期二, 四月 23, 2024
Monitoring, Cancer, Patient, Inflammation, Safety, Radiation, SJD, The Study, Therapy, Vice, Eye, Sant Joan, Enucleation of the eye, Pharmaceutical industry

ROCKVILLE, Md., April 23, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced positive topline data from the investigator sponsored Phase 1 trial conducted by collaborators at Sant Joan de Déu-Barcelona Children’s Hospital (SJD). The Phase 1 trial was designed to evaluate the safety and tolerability of two intravitreal injections of Theriva’s investigational oncolytic adenovirus VCN-01 in patients (n=9) with intraocular retinoblastoma that is refractory to chemotherapy or radiotherapy, and for whom enucleation was the only recommended treatment.

Key Points: 
  • “Results from the investigator sponsored trial further validate VCN-01’s unique mechanism of action and therapeutic potential to improve patient outcomes in otherwise refractory cancers,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.
  • “We look forward to building on the encouraging safety profile and antitumor activity, which further supports and informs the design of our proposed Phase 2 clinical trial.
  • The Monitoring Committee determined that the trial results were positive, and therefore, Theriva will receive an exclusive, worldwide license, and related patents from SJD for the treatment of pediatric patients with advanced retinoblastoma.
  • Eye enucleation was avoided in 3 patients to date, one of whom has retained their eye after 4 years of follow-up.

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

Retrieved on: 
星期一, 三月 25, 2024
Research, SJD, IDMC, Conference call, Conference, Retinoblastoma, Telephone, Patient, Acquisition, Cancer, VCN, Insurance, Bank statement, GMP, Clinical trial, Safety, Sant Joan, Therapy, Intravenous therapy, HCT, Pharmaceutical industry

ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the full-year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • The trial is expected to enroll 92 evaluable patients and remains on track to complete enrollment in H1 2024.
  • Other income for the year ended December 31, 2023 is primarily comprised of interest income of $1,439,000 and an exchange gain of $3,000.
  • Cash and cash equivalents totaled $23.2 million as of December 31, 2023, compared to $41.8 million as of December 31, 2022.
  • ET to discuss its financial results for the full-year ended December 31, 2023 and provide a corporate update.

Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting

Retrieved on: 
星期二, 一月 23, 2024
Child, Hearing loss, Lilly, Clinical trial, Gene, Medicine, Sant Joan, ABR, Eli Lilly and Company, Genetic testing, Division, HL, Hospital, ARO, FDA, Physician, Late, Hearing, Research, Diagnosis, LLY, SVP, Pharmaceutical industry

INDIANAPOLIS, Jan. 23, 2024 /PRNewswire/ -- Akouos, Inc., a wholly owned subsidiary of Eli Lilly and Company (NYSE: LLY), today announced positive initial clinical results from the Phase 1/2 AK-OTOF-101 study, which demonstrated pharmacologic hearing restoration within 30 days of AK-OTOF administration in the first participant, an individual with a decade-plus history of profound hearing loss. Results, including initial data from a second participant to receive AK-OTOF, will be presented during the Late Breaking Presidential Symposium at the 2024 Association for Research in Otolaryngology (ARO) MidWinter Meeting.

Key Points: 
  • Results, including initial data from a second participant to receive AK-OTOF, will be presented during the Late Breaking Presidential Symposium at the 2024 Association for Research in Otolaryngology (ARO) MidWinter Meeting.
  • Both the surgical administration procedure and the investigational therapy were well tolerated, and no serious adverse events were reported.
  • Millions of individuals worldwide have disabling hearing loss because one of their genes generates an incorrect or incomplete version of a protein the ear requires for hearing.
  • OTOF-mediated hearing loss is the first monogenic form of hearing loss to be investigated as part of a gene therapy clinical trial.

Comprehensive Review Highlights Importance of Leukine® in Combination with Anti-GD2 Immunotherapy for Treatment of High-Risk Pediatric Neuroblastoma

Retrieved on: 
星期三, 一月 17, 2024
Lazarus, Neutrophil, Macrophage, Therapy, Canadian International Council, Hook effect, Hematology, G-CSF, Sant Joan, Safety, Hospital, MHC, FDA, PTX, INT, GM-CSF, ADCC, B cell, Vaccine

LEXINGTON, Mass., Jan. 17, 2024 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) announced today the publication of a comprehensive review by Mora et al.

Key Points: 
  • LEXINGTON, Mass., Jan. 17, 2024 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) announced today the publication of a comprehensive review by Mora et al.
  • It also describes why the authors believe it is suboptimal to replace with Leukine with G-CSF in this regimen for mechanistic reasons.
  • Leukine has been studied extensively in combination with dinutuximab and naxitamab leading to improved patient outcomes.
  • As a result, all clinical trials supporting the FDA-approval of dinutuximab and naxitamab included Leukine and both products are labeled for use in combination with GM-CSF.

Theriva™ Biologics and Sant Joan de Déu-Barcelona Children’s Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer

Retrieved on: 
星期四, 十一月 2, 2023
Neoplasm, Child, Neuroblastoma, Adolescence, Topotecan, NYSE, Cancer, Therapy, Lung, Ewing sarcoma, Partnership, Sant Joan, SJD, Pharmaceutical industry

ROCKVILLE, Md. and BARCELONA, Spain, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, and Sant Joan de Déu-Barcelona Children’s Hospital (“SJD”), a university hospital specializing in maternal, child and adolescent health care, today announced that Theriva has executed an exclusive worldwide option to negotiate an exclusive license certain SJD intellectual property rights related to the use of VCN-01 in combination with topoisomerase I inhibitor chemotherapies for the treatment of cancer. VCN-01 is Theriva’s systemic, selective, stroma-degrading oncolytic adenovirus.

Key Points: 
  • The collaboration builds on growing data that suggests coadministration of VCN-01 with topoisomerase I inhibitors such as topotecan can enhance VCN-01 replication and antitumor activity in preclinical cancer models.
  • “Topoisomerase I inhibitors are used to treat a range of challenging tumors, including lung, cervical, colorectal, and pancreatic cancers as well as retinoblastoma.
  • Recent findings suggest that the combination of VCN-01 and topoisomerase I inhibitors may provide a synergistic antitumor effect to improve therapeutic outcomes in these indications.
  • Synergy happens through the effect of topotecan increasing the susceptibility of cancer cells to VCN-01 infection.

Y-mAbs Announces Publication in Cancers

Retrieved on: 
星期一, 十月 16, 2023
Sant Joan, Memorial Sloan Kettering Cancer Center, HITS, Mab, Interim, Naxitamab, Therapy, Safety, Patient, Temozolomide, MSK, EOI, Irinotecan, CR, Financial toxicity, Pharmaceutical industry, Nursing, Cancer

“The publication in Cancers further validates the utilization of naxitamab early during the course of treatment for patients with high-risk neuroblastoma,” said Thomas Gad, Founder, President and Interim Chief Executive Officer.

Key Points: 
  • “The publication in Cancers further validates the utilization of naxitamab early during the course of treatment for patients with high-risk neuroblastoma,” said Thomas Gad, Founder, President and Interim Chief Executive Officer.
  • Cycles were administered 3-5 weeks apart and the primary endpoint was overall response rate (CR + partial response (“PR”)).
  • The HITS combination did not appear to exacerbate the rate nor the intensity of infusion-related toxicities of naxitamab when observed as a stand-alone treatment.
  • Researchers at Memorial Sloan Kettering Cancer Center (MSK) developed DANYELZA® (naxitamab-gqgk), which is exclusively licensed by MSK to Y-mAbs.

Pharmactive Black Garlic Extract For Blood Pressure Management

Retrieved on: 
星期二, 二月 1, 2022
Risk, Mortality, LDL, Trial of the century, Garlic, Antioxidant, DBP, DASH, Capsule, Stroke, Man, Population, Adult, Flavonoid, Blood, Health, Diet, Ageing, Powder, Science, Blood pressure, Ethics, Sant Joan, Nutrient, SAC, Dietary supplement, Medicinal plants, Victoria Espinel, ABG

's Aged Black Garlic (ABG+) demonstrated new potential to balance blood pressure favorably.

Key Points: 
  • 's Aged Black Garlic (ABG+) demonstrated new potential to balance blood pressure favorably.
  • Results at six weeks demonstrated that ABG+ extract significantly reduced diastolic blood pressure (DBP) by 5.85mm Hg on average compared to the placebo.
  • "A reduction of just 5mm Hg of diastolic blood pressure lowers substantially the risk of stroke and other vascularevents," explainsAlberto Espinel, Head of R&D for Pharmactive.
  • Pharmactive Biotech Products, S.L.U., is a Madrid-based pioneering biotechnology company that develops and manufactures differentiated natural ingredients supported by science, such as pure saffron extract and aged black garlic.

Philips expands Augmented Reality Surgical Navigation – ClarifEye – to two new international sites with successful clinical outcomes

Retrieved on: 
星期三, 十二月 1, 2021
Philips, Surgeon, Regional hospital, NYSE, Physician, Literature, Risk, Karolinska University Hospital, Vertebral column, Augmented reality, PHG, Hospital, University, 2D, The Spine Journal, University Medical Center, Orthopedic surgery, University Medical Center Schleswig Holstein, Human, World Neurosurgery, Joint, Trial of the century, Spinal fusion, Spinal canal, UNESCO Science Report, Adult, CT, Pain, Quality of life, Patient, Skin, AR, Technology, Deformity, Review, Spine, 3D, Spondylolisthesis, Hudson Regional Hospital, AEX, Sant Joan, Medical imaging, Medical device

Using the Philips spine solution, pedicle screws were successfully placed at four spine levels to fuse several lumbar vertebras.

Key Points: 
  • Using the Philips spine solution, pedicle screws were successfully placed at four spine levels to fuse several lumbar vertebras.
  • ClarifEye Augmented Reality Surgical Navigation was introduced earlier this year .
  • Philips is a pioneer in Hybrid OR solutions and innovating surgical navigation technology, which helps surgeons perform image-guided, open and minimally invasive spine surgery.
  • [3] Elmi-Terander at el, Augmented reality navigation with intraoperative 3D imaging vs fluoroscopy-assisted free-hand surgery for spine fixation surgery, a matched-control study, Nature Sci.

The PortAventura Foundation and the Ricky Rubio Foundation sign an agreement at Dreams

Retrieved on: 
星期三, 九月 8, 2021

BARCELONA, Spain, Sept. 8, 2021 /PRNewswire/ --The PortAventura Foundation and the Ricky Rubio Foundation have entered into a partnership agreement to help families in vulnerable situations that are also living with a child undergoing cancer treatment.

Key Points: 
  • BARCELONA, Spain, Sept. 8, 2021 /PRNewswire/ --The PortAventura Foundation and the Ricky Rubio Foundation have entered into a partnership agreement to help families in vulnerable situations that are also living with a child undergoing cancer treatment.
  • The first phase of this joint social project will begin with a week-long stay in the PortAventura Dreams Village for a family as part of the Ricky Rubio Foundation's Luca Project.
  • This recreational space, which was opened by the PortAventura Foundation in October 2019, aims to have a positive impact on patient recovery from a psychological point of view, allowing interaction with their environment and other families dealing with similar illnesses.
  • The stay also includes access to the three parks of PortAventura World and to the Cruyff Court, a football pitch where they can take part in physical activities.